$CBIO potential to make a large move 🔥$CBIO looks like it has potential to make a large move soon, Also it's #4 in list of top Fintel Gamma Squeeze list📈
CBIO trade ideas
CBIO CBIO = my return will focus only on a few stocks to keep .. minimum 5 days max 1 month ... MARKETS SHOW PANIC IS THE PERFECT TIME TO INVEST IN CONTRARIAN PHARMACEUTICAL ... This company has También noté in the super column green an incremental increase de volumen, que puede haber sido verificado ... in the triangles of the previous movements, mi punto es que el volumen en entry there can be in short an including muy fuerte ... ME ENCANTA ESE TYPE OF CONFIGURATION .. Let's see that proudly replies ..
good trade
CBIO - FALLING WEDGE PLAY - 15-30% HERE - 30M FLOAT - NO DEBTAll,
I think CBIO is a good play down here maybe wait and see for the break, but overall should be an easy pop. Also end of 2021 or before first dosed patient results. Combination would be deadly at least a 30%er if positive. Low enough float to play with TA alone though.
TightIf it stays tight around the $6.0-6.8 range until March we will see a break either up or down and I possibly will ride the wave.
$CBIO Cup and Handle?this one has amazing potential for the long term
had a nice run with this one last week for 50% profits. kept a small core position that i will be adding to for long
i61.CBIOBeta-R:Journal. Risk Management: Compound .Level : PA . Time: Short-term - Intermediate . This is just my view follow if it aligns with yours. Ideas are not repeated rather updated.Worry about risk only.
CBIO - DAILY CHART Hi, today we are going to talk about Catalyst Biosciences and its current landscape.
Catalyst Biosciences is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company has been soaring over the announcement that the company entered into a global science collaboration agreement with Biogen for the development and commercialization of pegylated CB-2782. Catalyst Biosciences it's going to receive $15 million upfront payment and is poised to receive up to $340 million down the road, also royalties of the sales. A context that sets Catalyst Biosciences to a skyrocket movement as is expected that its earnings are going to overcome expectations in the next quarters easily than ever.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
$CBIO MAY BE SLOWLY GETTING READY TO ATTACK "GAP" TERRITORYUptick in volume and relatively clean sky above 200 SMA
VOLUME HAS SPIKED IN ANTICIPATION OF POSITIVE CLINICAL DATA CATALYST BIOSCIENCES INC CBOE ($CBIO)
CBIO will release at the ISTH conference final Phase 2 data for marzeptaacog alfa in hemophilia.Dr. Johnny Mahlangu, M.D., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and a principal investigator on the MarzAA Phase 2 study, will deliver an oral presentation on the final data from the Company's next-generation engineered subcutaneous (SQ) coagulation Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) Phase 2 trial for the treatment of hemophilia A or B with inhibitors. Additionally, the Company will have three posters covering (1) quality of life improvements for subjects in the Phase 2 MarzAA trial, (2) in silico and in vitro immunogenicity risk assessment of its next-generation engineered SQ coagulation Factor IX (FIX), dalcinonacog alfa (DalcA) compared with wildtype FIX and (3) the ongoing Phase 2b study of DalcA.
COMPANY PROFILE
COMPANY PROFILE
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.
CBIO momo uptrend FDA news comingshort term target on chart
see some MOMO until FDA news coming out
07/18/2018
Phase 2 commencement of Part 2 of Phase 2/3 trial announced January 4, 2018. Interim data due at ISTH July 18, 2018. Final data due at ASH 2018.
potential gapper candidate
Triangle breakout cbio has been popping up multiple times on my scans playing around in my action zone between the 10ma and 30ema with 5 consecutive down days + nr7 inside day on low volume. Looks to be holding those supports quite well, triangulating and Volume has been drying up nicely. I would normally like to get in just above that inside days high but with current market timing i will wait for the breakout.
CBIO - Fallen angel formation Day trade from $4.70 to $4.94CBIO seems forming a very nice fallen angel formation. It has history of sharp breakout, and at this time it seems getting ready for another breakout. We are looking for a quick day trade if it breaks above $4.70
* Trade Criteria *
Date First Found- June 29, 2017
Pattern/Why- Fallen angel formation
Entry Target Criteria- Break of $4.70
Exit Target Criteria- $4.94
Stop Loss Criteria- $4.60
Please check back for Trade updates. (Note: Trade update is little delayed here.)
Potential Long position CBIOU.S. Government Required Disclaimer - Commodity Futures Trading Commission Futures, Stocks and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures, stocks or options on the same. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.
CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.
NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL, OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE DISCUSSED WITHIN THIS SITE, SUPPORT AND TEXTS. OUR COURSE(S), PRODUCTS AND SERVICES SHOULD BE USED AS LEARNING AIDS ONLY AND SHOULD NOT BE USED TO INVEST REAL MONEY. IF YOU DECIDE TO INVEST REAL MONEY, ALL TRADING DECISIONS SHOULD BE YOUR OWN.
Newest Alert is $CBIO$CBIO Recent Highlights and Upcoming Milestones
Recent Highlights:
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million.
Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million
The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months.
Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017
Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows:
Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS)
Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis
Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments:
Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed
Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor
Anticipated Milestones
CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea
Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017
stocks can be a jackpot more than forex some timesexpect long this stock for april, then drop from higher?? might be.
anyway i expect a 200% return at least. if more might be my jackpot :D small stop
CBIO- Interesting Stock- Why Up?Why did CBIO stock shares practically triple? On longer charts,stock worth over $3,000 share once.
Catalyst Biosciences Inc. (CBIO) saw its shares practically triple in Tuesday’s session after the company announced a critical regulatory approval. The company reported that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug Application (IND) for CB 2679d/ISU304, which works to treat individuals with hemophilia.
Hemophilia is a serious bleeding disorder that results in spontaneous bleeding episodes, as well as substantially prolonged bleeding times upon injury.
Terms of drug, it is a highly potent next-generation coagulation Factor IX variant, demonstrated potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. In simpler terms, CB2679d/ISU304 works to inhibit blood loss and can be used as a preventative treatment to individuals with hemophilia. * F.Y.I for possible investment in.
CBIO long, 4$ upside potentialCBIO, very low float, former runner, better earnings then expected, no real resistance before 10.50$, long there.
